| A | B | C | D | E | F | G | H | I | J | |
|---|---|---|---|---|---|---|---|---|---|---|
1 | CLINICAL TRIALS - OVARIAN CANCER | |||||||||
2 | PRIMARY PERITONEAL CARCINOMA | |||||||||
3 | Source: clinicaltrials.gov | |||||||||
4 | ||||||||||
5 | ICAN advises every patient and other interested person, after reviewing this clinical trials spreadsheet, to check out clinical trials directly at www.cancer.gov in case there are updates since the date of this posting. ICAN does not purport to provide medical advice or to indicate which trial is suitable for a certain patient. Please consult your medical oncology team and the principal investigator in charge of the trial in which you are interested for information most relevant to your specific medical situation and decision-making process. | Contact Information | ||||||||
6 | No. | Link | Title | Official Title | Purpose | Citation | Organization/Sponsor | Collaborator | Status | Criteria |
7 | ||||||||||
8 | 1 | http://clinicaltrials.gov/ct2/show/NCT00770536 | A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer | A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer | This study is a 2 part, 2 cohort, open-label, dose escalation/de escalation study of AMG 386 in combination with either pegylated liposomal doxorubicin or topotecan in subjects with recurrent ovarian cancer. Up to 100 subjects will be enrolled to receive AMG 386 in combination with either pegylated liposomal doxorubicin every 4 weeks (cohort A) or topotecan weekly on days 1, 8, and 15 of a 28 day dosing schedule (cohort B). Subject enrollment and assignment to either cohort will be based on eligibility and the investigator's discretion. It is hypothesized that AMG 386, in combination with each of the chemotherapy regimens: either pegylated liposomal doxorubicin or topotecan will be safe and well tolerated in subjects with recurrent ovarian cancer. | http://clinicaltrials.gov/ct2/show/NCT00770536 - Retrieved April 2012 | Amgen | Currently recruiting | Advanced / Recurrent | |
9 | 2 | http://clinicaltrials.gov/ct2/show/NCT01443260 | A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis | Phase I/II Study of Intraperitoneal Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Peritoneal Carcinomatosis | The purpose of this study is to determine whether GL-ONC1, an attenuated vaccinia virus, is safe when administered to patients with peritoneal carcinomatosis via an infusion within the abdominal cavity through an implanted catheter. The study seeks also to arrive at a recommended dose and schedule for future investigations, evidence of anti-tumor activity, detection of virus in body fluids, analysis of viral delivery to tumor and normal cells, and to evaluate if there is an antibody response to vaccinia virus. | http://clinicaltrials.gov/ct2/show/NCT01443260 - Retrieved April 2012 | Genelux GmbH | Currently recruiting | Advanced | |
10 | 3 | http://clinicaltrials.gov/ct2/show/NCT01264432 | ABT-888 in Combo of LDFWAR to Treat Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis | A Phase I Study of Veliparib (ABT-888) in Combination With Low-dose Fractionated While Abdominal Radiation Therapy (LDFWAR) in Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis. | Refer to clinical trials website. | http://clinicaltrials.gov/ct2/show/NCT01264432 - Retrieved April 2012 | Sidney Kimmel Comprehensive Cancer Center | National Cancer Institute | Currently recruiting | Advanced |
11 | 4 | http://clinicaltrials.gov/ct2/show/NCT01306032 | ABT-888 With Cyclophosphamide in Refractory BRCA-Positive Ovarian, Primary Peritoneal or Ovarian High-Grade Serous Carcinoma, Fallopian Tube Cancer, Triple-Negative Breast Cancer, and Low-Grade Non-Hodgkin's Lymphoma | Ph II Randomized Trial of the Combination of ABT-888 With Metronomic Oral Cyclophosphamide in Refractory BRCA-Pos Ovarian, Primary Peritoneal or Ovarian High-Grade Serous Carcinoma, Fallopian Tube Cancer, Triple-Neg Breast Cancer | Refer to clinical trials website. | http://clinicaltrials.gov/ct2/show/NCT01306032 - Retrieved April 2012 | National Cancer Institute | Currently recruiting | Metastatic | |
12 | 5 | http://clinicaltrials.gov/ct2/show/NCT01492920 | Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy | A Randomized, Double-Blind, Placebo Controlled Phase III Trial Using ACETYL-L-Carnitine (ALC) (NSC# 747431) for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | This randomized phase III trial studies how well acetyl-L-carnitine hydrochloride works compared to a placebo in preventing peripheral neuropathy in patients with recurrent ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer undergoing chemotherapy | http://clinicaltrials.gov/ct2/show/NCT01492920 - Retrieved April 2012 | Gynecologic Oncology Group | National Cancer Institute | Not yet recruiting | Recurrent |
13 | 6 | http://clinicaltrials.gov/ct2/show/NCT01442051 | Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer | A Pilot Study of Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer | Refer to clinical trial website. | http://clinicaltrials.gov/ct2/show/NCT01442051 - Retrieved April 2012 | Memorial Sloan-Kettering Cancer Center | Currently recruiting | Advanced | |
14 | 7 | http://clinicaltrials.gov/ct2/show/NCT01039207 | AMG 102 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | A Phase II Evaluation of AMG 102 (IND # 107579, NSC #750009) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma | This phase II trial is studying how well AMG 102 works in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. | http://clinicaltrials.gov/ct2/show/NCT01039207 - Retrieved April 2012 | Gynecologic Oncology Group | National Cancer Institute | Currently recruiting | Recurrent |
15 | 8 | http://clinicaltrials.gov/ct2/show/NCT00562640 | Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009) | A Phase I Dose Escalation Safety and Feasibility Study of WT1-Specific T Cells for the Treatment of Patients With Advanced Ovarian, Primary Peritoneal, and Fallopian Tube Carcinomas | This phase I trial is studying the side effects and best dose of autologous T cells when given with or without cyclophosphamide and fludarabine in treating patients with recurrent or persistent advanced ovarian epithelial cancer, primary peritoneal cavity cancer, or fallopian tube cancer. (fludarabine treatment closed as of 12/012009) | http://clinicaltrials.gov/ct2/show/NCT00562640 - Retrieved April 2012 | Memorial Sloan-Kettering Cancer Center | National Cancer Institute | Currently recruiting | Advanced / Recurrent |
16 | 9 | http://clinicaltrials.gov/ct2/show/NCT01312376 | Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer | A Phase-1 Trial of Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Combined With Vaccine Boost and Bevacizumab for Recurrent Ovarian Fallopian Tube or Primary Peritoneal Cancer Previously Vaccinated With Autologous Tumor Vaccine | This is a phase -1 clinical trial to determine the feasibility and safety of cyclophosphamide/fludarabine lymphodepletion followed by adoptive transfer of vaccine-primed, ex vivo CD3/CD28-costimulated peripheral blood autologous T-cells, followed by vaccination with OC-DC, an autologous dendritic cell (DC) vaccine loaded with autologous oxidized tumor cells, administered intradermally in combination with Bevacizumab in patients with recurrent ovarian cancer, fallopian tube or primary peritoneal cancer. | http://clinicaltrials.gov/ct2/show/NCT01312376 - Retrieved April 2012 | Abramson Cancer Center of the University of Pennsylvania | Currently recruiting | Recurrent | |
17 | 10 | http://clinicaltrials.gov/ct2/show/NCT01305213 | Bevacizumab With or Without Fosbretabulin Tromethamine in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | A Randomized Phase II Evaluation of Single-Agent Bevacizumab (IND #7921) (NSC #704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC #752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma | This randomized phase II trial is studying how well giving bevacizumab with or without fosbretabulin tromethamine works in treating patients with ovarian epithelial, fallopian tube, or peritoneal cavity cancer. | http://clinicaltrials.gov/ct2/show/NCT01305213 - Retrieved April 2012 | Gynecologic Oncology Group | National Cancer Institute | Currently recruiting | Recurrent |
18 | 11 | http://clinicaltrials.gov/ct2/show/NCT01314105 | BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Ovarian Cancer (OC) | Phase I Dose Escalation Trial to Determine the Maximum Tolerated Dose of BIBF 1120 in Combination With Carboplatin and Pegylated Liposomal Doxorubicin (PLD) in Patients With a First, Second or Third Platinum Sensitive Relapse of Advanced Epithelial Ovarian Cancer, Fallopian Tube or Primary Peritoneal Cancer | This phase I, open label dose escalation study will investigate the addition of BIBF 1120 to treatment with the combination of carboplatin and Pegylated Liposomal Doxorubicin (PLD) in patients with advanced, platinum sensitive relapsed ovarian cancer, fallopian tube carcinoma or primary peritoneal cancer. | http://clinicaltrials.gov/ct2/show/NCT01314105 - Retrieved April 2012 | Boehringer Ingelheim Pharmaceuticals | Currently recruiting | Advanced | |
19 | 12 | http://clinicaltrials.gov/ct2/show/NCT00565851 | Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer | Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination With Bevacizumab (NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreduction Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer | This randomized phase III trial is studying giving carboplatin and paclitaxel together with or without bevacizumab after surgery to see how well it works in treating patients with recurrent ovarian epithelial cancer, primary peritoneal cavity cancer, or fallopian tube cancer | http://clinicaltrials.gov/ct2/show/NCT00565851 - Retrieved April 2012 | Gynecologic Oncology Group | National Cancer Institute | Currently recruiting | Recurrent / Metastatic |
20 | 13 | http://clinicaltrials.gov/ct2/show/NCT01540344 | Combined Anticancer Treatment of Advanced Colon Cancer (COMBATAC) | Multimodality Treatment Including Pre- and Postoperative Systemic Chemotherapy Plus Cetuximab, Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis Arising From Wild Type K-ras Colon Cancer: A Prospective Multicenter Phase II Study. | The COMBATAC study evaluates the the effect as assessed by progression-free survival (PFS) of perioperative systemic chemotherapy including cetuximab and cytoreductive surgery (CRS) and bidirectional hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal carcinomatosis arising from colorectal cancer. | http://clinicaltrials.gov/ct2/show/NCT01540344 - Retrieved April 2012 | University of Regensburg | Heinrich-Heine University, Duesseldorf | Currently recruiting | Advanced / Metastatic |
21 | 14 | http://clinicaltrials.gov/ct2/show/NCT01180504 | Consolidation Whole Abdominal Intensity-Modulated Radiation Therapy (IMRT) in Advanced Ovarian Cancer (OVAR-IMRT-02) | Consolidation Intensity-Modulated Whole Abdominal Radiotherapy for High-Risk Patients With Ovarian Cancer Stage FIGO III | The primary objective of this phase-II study is to assess the toxicity of consolidation intensity-modulated whole-abdominal radiotherapy using tomotherapy in patients with advanced optimally debulked stage International Federation of Gynecology and Obstetrics (FIGO) III ovarian cancer with a complete remission after adjuvant chemotherapy. 36 patients will be treated to a total dose of 30 Gy in 1.5 Gy fractions. The planning target-volume includes the entire peritoneal cavity and the pelvic and para-aortal node regions. Intensity-modulated whole-abdominal radiotherapy allows an effective sparing of liver, kidneys and bone-marrow (vertebral bodies and pelvic bones). | http://clinicaltrials.gov/ct2/show/NCT01180504 - Retrieved April 2012 | University Hospital Heidelberg | Deutsche Krebshilfe e.V., Bonn (Germany) | Currently recruiting | Advanced |
22 | 15 | http://clinicaltrials.gov/ct2/show/NCT01116791 | Cytoreductive Surgery(CRS) Plus Hyperthermic Intraoperative Peritoneal Chemotherapy(HIPC) With Cisplatin to Treat Peritoneal Carcinomatosis From Upper Gastrointestinal Cancer | Cytoreductive Surgery Plus Hyperthermic Intraoperative Peritoneal Chemotherapy With Cisplatin to Treat Peritoneal Carcinomatosis From Upper Gastrointestinal Cancer; the HIPCUpp-trial | The majority of patients with upper gastrointestinal cancer, such as gastric, biliary, or pancreatic carcinoma, present with metastatic disease, and have an extremely poor survival, irrespective the type of treatment modality. The aim of the current monocentric phase II study is to evaluate in these patients the effectiveness of cytoreductive surgery (CRS) plus hyperthermic intraoperative peritoneal chemotherapy with cisplatin (HIPC). The study is designed to have at least 80% power to detect a 40% increase in 1-year overall survival common to all strata (gastric-biliary-pancreas) after CRS+HIPC. Over an anticipated period of 2 years, 60 patients will undergo CRS + HIPC. Translational research will quantify perioperative circulating and peritoneal tumour cells, based on real-time RT-PCR for CEA and EpCAM. Plasma concentration of cytokines will be determined for IL-1β, IL-2, IL-6, IL-8, IL-10, IL-12p70, IL-13, IFN-γ, and VEGF at several time-points. Systemic immunological changes will be assessed by flow cytometric quantification of the relative proportions and absolute numbers of B- and T-lymphocytes, NK cells, effector T cells, HLA-DR+ T cells, and regulatory T cells. Gene-expression studies will be performed using Affymetrix HG U133 Plus 2.0 arrays on primary and metastatic tissue samples. | http://clinicaltrials.gov/ct2/show/NCT01116791 - Retrieved April 2012 | University Hospital, Gasthuisberg | Currently recruiting | Recurrent / Metastatic | |
23 | 16 | http://clinicaltrials.gov/ct2/show/NCT01329549 | Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC) | An Open-label, Dose Escalation Phase I Study of the Safety and Tolerability of BIBF 1120 in Combination With Carboplatin and Pegylated Liposomal Doxorubicin (PLD) in Japanese Patients With a First, Second or Third Platinum-sensitive Relapse of Advanced Epithelial Ovarian Cancer, Fallopian Tube or Primary Peritoneal Cancer. | This phase I, open label dose escalation study will investigate the addition of BIBF 1120 to treatment with the combination of carboplatin and Pegylated Liposomal Doxorubicin (PLD) in patients with advanced, platinum sensitive relapsed ovarian cancer, fallopian tube carcinoma or primary peritoneal cancer. Patients will be treated with BIBF 1120 together with carboplatin and PLD in up to 6-9 repeated 28 days treatment courses until disease progression is observed. | http://clinicaltrials.gov/ct2/show/NCT01329549 - Retrieved April 2012 | Boehringer Ingelheim Pharmaceuticals | Currently recruiting | Advanced | |
24 | 17 | http://clinicaltrials.gov/ct2/show/NCT01489371 | EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | A Phase I Study of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) (IND #12,484) Administered in Combination With Pegylated Liposomal Doxorubicin (PLD, Doxil (NSC #712227 or Lipodox) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | This phase I trial studies the side effects and the best dose of giving EGEN-001 together with pegylated liposomal doxorubicin hydrochloride in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. | http://clinicaltrials.gov/ct2/show/NCT01489371 - Retrieved April 2012 | Gynecologic Oncology Group | National Cancer Institute | Not yet recruiting | Recurrent |
25 | 18 | http://clinicaltrials.gov/ct2/show/NCT01381861 | Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma | A Phase 2 Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma | The purpose of this study is to evaluate the safety and efficacy of TRC105 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. | http://clinicaltrials.gov/ct2/show/NCT01381861 - Retrieved April 2012 | Tracon Pharmaceuticals Inc. | Currently recruiting | Recurrent | |
26 | 19 | http://clinicaltrials.gov/ct2/show/NCT01535157 | Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer | Phase I/II Trial of Fenretinide/LXS Oral Powder (NSC 374551) Plus Ketoconazole in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma | The purpose of this study is to determine the effectiveness of fenretinide (4-HPR/LXS) plus ketoconazole in the treatment of recurrent ovarian cancer or primary peritoneal carcinoma. In addition, researchers would like to determine if the drugs are most effective together or if fenretinide (4-HPR/LXS) is most effective alone. | http://clinicaltrials.gov/ct2/show/NCT01535157 - Retrieved April 2012 | South Plains Oncology Consortium | Currently recruiting | Recurrent | |
27 | 20 | http://clinicaltrials.gov/ct2/show/NCT00968799 | Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study | Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study | Refer to clinical trials website. | http://clinicaltrials.gov/ct2/show/NCT00968799 - Retrieved April 2012 | Cantonal Hospital of St. Gallen | Currently recruiting | Recurrent | |
28 | 21 | http://clinicaltrials.gov/ct2/show/NCT01511055 | Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand | Phase II, Prospective, Non-Randomized Trial Investigating the Intra-Operative Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand | Refer to clinical trials website. | http://clinicaltrials.gov/ct2/show/NCT01511055 - Retrieved April 2012 | Mayo Clinic | Currently recruiting | Metastatic | |
29 | 22 | http://clinicaltrials.gov/ct2/show/NCT01074411 | Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | A Phase I Pharmacokinetic Study of Intraperitoneal CTEP-Supplied Agent Bortezomib (PS-341, NSC 681239, IND# 58443) and Carboplatin (NSC# 241240) in Patients With Persistent or Recurrent, Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | This phase I trial is studying the side effects and best dose of intraperitoneal bortezomib when given together with intraperitoneal carboplatin in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. | http://clinicaltrials.gov/ct2/show/NCT01074411 - Retrieved April 2012 | Gynecologic Oncology Group | National Cancer Institute | Currently recruiting | Recurrent |
30 | 23 | http://clinicaltrials.gov/ct2/show/NCT00575952 | Intraperitoneal Paclitaxel, Doxorubicin, and Cisplatin in Treating Patients With Endometrial Cancer | A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure | This phase I trial is studying the side effects and best dose of intraperitoneal paclitaxel when given together with doxorubicin and cisplatin in treating patients with endometrial cancer. | http://clinicaltrials.gov/ct2/show/NCT00575952 - Retrieved April 2012 | Gynecologic Oncology Group | National Cancer Institute | Currently recruiting | Recurrent |
31 | 24 | http://clinicaltrials.gov/ct2/show/NCT01091259 | Irinotecan and Bevacizumab for Recurrent Ovarian Cancer | Phase II Study of Irinotecan in Combination With Bevacizumab for the Treatment of Recurrent Ovarian Cancer. | The purpose of the study is to evaluate the efficacy and toxicity of irinotecan in the treatment of women with recurrent epithelial ovarian cancer or primary peritoneal cancer when combined with bevacizumab. | http://clinicaltrials.gov/ct2/show/NCT01091259 - Retrieved April 2012 | New York University School of Medicine | Genentech | Currently recruiting | Recurrent |
32 | 25 | http://clinicaltrials.gov/ct2/show/NCT01091428 | MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer | Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients With Ovarian or Breast Cancer | This is an open-label, multicenter study with a nonrandomized Phase 1 portion and an open-label, randomized, Phase 2 portion evaluating MLN8237 in combination with weekly paclitaxel in adult female patients with advanced breast cancer (Phase 1 portion only) and recurrent ovarian cancer (both Phase 1 and Phase 2 portions). | http://clinicaltrials.gov/ct2/show/NCT01091428 - Retrieved April 2012 | Millennium Pharmaceuticals, Inc. | Currently recruiting | Advanced / Recurrent | |
33 | 26 | http://clinicaltrials.gov/ct2/show/NCT00491855 | Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis | Phase I Trial of Intraperitoneal Oxaliplatin and Paclitaxel Plus Intravenous Paclitaxel and Bevacizumab in the Treatment of Advanced Peritoneal Carcinomatosis | The goal of this clinical research is to learn acceptable dosages of paclitaxel, oxaliplatin, and Avastin (bevacizumab) that can be given in combination to patients with advanced peritoneal carcinomatosis. The safety of this drug combination will also be studied. | http://clinicaltrials.gov/ct2/show/NCT00491855 - Retrieved April 2012 | M.D. Anderson Cancer Center | Currently recruiting | Advanced | |
34 | 27 | http://clinicaltrials.gov/ct2/show/NCT00108745 | Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer | A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) (IND# 70177), Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian or Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy | This randomized phase III trial is studying paclitaxel to see how well it works compared to polyglutamate paclitaxel or observation only in treating patients with stage III or stage IV ovarian epithelial or peritoneal cancer or fallopian tube cancer. | http://clinicaltrials.gov/ct2/show/NCT00108745 - Retrieved April 2012 | Gynecologic Oncology Group | National Cancer Institute | Currently recruiting | Advanced |
35 | 28 | http://clinicaltrials.gov/ct2/show/NCT01468909 | Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | A Randomized Phase II Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754) (IND #75648) Versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma | This randomized phase II trial is studying how well giving paclitaxel with or without pazopanib hydrochloride works in treating patients with persistent or recurrent ovarian epithelial, fallopian tube, or peritoneal cavity cancer. | http://clinicaltrials.gov/ct2/show/NCT01468909 - Retrieved April 2012 | Gynecologic Oncology Group | National Cancer Institute | Currently recruiting | Recurrent |
36 | 29 | http://clinicaltrials.gov/ct2/show/NCT00976183 | Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma | A Phase I/II, Open-Label, Non-Randomized, Pilot Study of Weekly Paclitaxel, Every Four-week Carboplatin and Oral Vorinostat for Patients Newly Diagnosed With Stage III/IV Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | Since the mortality rates for patients with advanced ovarian carinoma are high, the most likely way to improve progression free and overall survival is with maximal "upfront" therapy (Morrow & Curtin, 1998). Currently, no triplet regimen has demonstrated compelling superiority. Therefore, the combination of Paclitaxel, Carboplatin, and Vorinostat is intriguing because of their potential synergy, distinct mechanisms of action, and non-overlapping toxicity. | http://clinicaltrials.gov/ct2/show/NCT00976183 - Retrieved April 2012 | Gynecologic Oncology Associates | Merck | Currently recruiting | Advanced |
37 | 30 | http://clinicaltrials.gov/ct2/show/NCT01402271 | Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | Phase IB-II, Open Label, Multicenter Feasibility Study of Pazopanib in Combination With Paclitaxel and Carboplatin in Patients With Platinum-Refractory/Resistant Ovarian, Fallopian Tube or Peritoneal Carcinoma | This randomized phase I/II trial is studying the side effects and best dose of pazopanib hydrochloride when given together with paclitaxel and carboplatin in treating patients with refractory or resistant ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer. | http://clinicaltrials.gov/ct2/show/NCT01402271 - Retrieved April 2012 | European Organization for Research and Treatment of Cancer - EORTC | Not yet recruiting | Recurrent | |
38 | 31 | http://clinicaltrials.gov/ct2/show/NCT01001910 | Pemetrexed and Carboplatin in Recurrent Platinum Sensitive Ovarian Cancer | Phase II Trial of Combination Pemetrexed (Alimta) and Carboplatin (Paraplatin) in Platinum Sensitive Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma | The purpose of this study is to determine the effects (good and bad) the combination of carboplatin and pemetrexed have on patients with recurrent ovarian, peritoneal, or fallopian tube cancer. | http://clinicaltrials.gov/ct2/show/NCT01001910 - Retrieved April 2012 | Montefiore Medical Center | Currently recruiting | Recurrent | |
39 | 32 | http://clinicaltrials.gov/ct2/show/NCT00826150 | Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer | Phase 1/2a, Dose-Escalation, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Intraperitoneal Administration of DTA-H19 in Subjects With Advanced Stage Ovarian Cancer | This study is designed to assess the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of DTA-H19 administered intraperitoneally (IP) in subjects with advanced stage ovarian cancer, or primary peritoneal carcinoma. | http://clinicaltrials.gov/ct2/show/NCT00826150 - Retrieved April 2012 | BioCancell Therapeutics Israel Ltd. | Currently recruiting | Advanced | |
40 | 33 | http://clinicaltrials.gov/ct2/show/NCT01249859 | Prognosis of Signet Ring Cells in Upper Digestive Neoplasms (ADCI001) | Has the Quota of Signet Ring Cells an Influence on Prognosis and Treatment Strategy in the Upper GI Tract Adenocarcinomas? | Refer to clinical trials website. | http://clinicaltrials.gov/ct2/show/NCT01249859 - Retrieved April 2012 | University Hospital, Lille | Currently recruiting | Advanced | |
41 | 34 | http://clinicaltrials.gov/ct2/show/NCT00408590 | Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer | Phase I Trial of Intraperitoneal Administration of a) a CEA-Expressing Derivative, and b) a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer | This phase I trial is studying the side effects and best dose of an attenuated oncolytic measles virus therapy and oncolytic virus therapy in treating patients with progressive, recurrent, or refractory ovarian epithelial cancer or primary peritoneal cancer (measles virus vaccine therapy study closed as of 06/02/2008). | http://clinicaltrials.gov/ct2/show/NCT00408590 - Retrieved April 2012 | Mayo Clinic | National Cancer Institute | Currently recruiting | Recurrent |
42 | 35 | http://clinicaltrials.gov/ct2/show/NCT01004861 | Safety Study of PLX108-01 in Patients With Solid Tumors | A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX3397 in Patients With Advanced, Incurable, Solid Tumors in Which the Target Kinases Are Linked to Disease Pathophysiology | PLX3397 is a selective inhibitor of Fms, Kit, and oncogenic Flt3 activity. The primary objective of this study is to evaluate the safety and pharmacokinetics of orally administered PLX3397 in patients with advanced, incurable, solid tumors in which these target kinases are linked to disease pathophysiology. The secondary objective is to measure the pharmacodynamic activity of PLX3397 via plasma and urine biomarkers of Fms activity. | http://clinicaltrials.gov/ct2/show/NCT01004861 - Retrieved April 2012 | Plexxikon | Currently recruiting | Advanced / Metastatic | |
43 | 36 | http://clinicaltrials.gov/ct2/show/NCT01391351 | Search for Predictors of Therapeutic Response in Ovarian Carcinoma (miRSa) | Search for Predictors of Therapeutic Response in Patients With Carcinoma of the Ovary, the Fallopian Tube or Peritoneal Serous-type Advanced | In order to search for predictors of response to chemotherapy in patients with ovarian carcinoma of the ovary, the fallopian tube or peritoneal serous-type advanced stage, we will define the comparative profiles of miRNA expression of serum polymorphisms and determine differential in 2 patient populations (with or without recurrence 6 months after completion of chemotherapy) with (i) the miRNA profile of serum before treatment and (ii) identification of polymorphisms or SNP (Single Nucleotide Polymorphism) in particular genes involved in the metabolism of chemotherapy agents In the case of miRNA, expression profiles will also be studied during the first course in response to chemotherapy. Indeed, the miRNA profile of serum may be different at baseline among the 2 types of populations (or non-recurrence at 6 months). | http://clinicaltrials.gov/ct2/show/NCT01391351 - Retrieved April 2012 | Centre Francois Baclesse | Currently recruiting | Advanced | |
44 | 37 | http://clinicaltrials.gov/ct2/show/NCT01200797 | SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin | A Phase II Evaluation of SJG-136 in Women With Cisplatin-Refractory or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma | This phase II trial is studying how well SJG-126 works in treating patients with epithelial ovarian, primary peritoneal, or fallopian tube cancer that did not respond to previous treatment with cisplatin or carboplatin. | http://clinicaltrials.gov/ct2/show/NCT01200797 - Retrieved April 2012 | H. Lee Moffitt Cancer Center and Research Institute | National Cancer Institute | Currently recruiting | Recurrent |
45 | 38 | http://clinicaltrials.gov/ct2/show/NCT01220154 | Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer (OSU09115) | Phase I Study of Intraperitoneal Carboplatin With Intravenous Paclitaxel and Bevacizumab in Patients With Previously Untreated Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma | Phase I study to evaluate intraperitoneal carboplatin along with weekly intravenous paclitaxel and bevacizumab in order to establish a tolerable dose and define the toxicity of this regimen in previously untreated patients with advanced ovarian carcinoma. | http://clinicaltrials.gov/ct2/show/NCT01220154 - Retrieved April 2012 | Ohio State University | Currently recruiting | Advanced | |
46 | 39 | http://clinicaltrials.gov/ct2/show/NCT01035658 | Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma | A Phase I/II Study of the Combination of Pazopanib and Liposomal Doxorubicin (Doxil) in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma | In this study, patients with relapsed or refractory ovarian cancer will receive treatment with pazopanib and liposomal doxorubicin (Doxil) until disease progression or unacceptable toxicity occurs. The Phase I portion will define the dose limiting toxicity (DLT) of pazopanib and liposomal doxorubicin when administered in combination. Once the maximum tolerated dose has been identified in the Phase I portion, the Phase II portion will evaluate efficacy and safety of this combination in the same patient population. | http://clinicaltrials.gov/ct2/show/NCT01035658 - Retrieved April 2012 | Sarah Cannon Research Institute | GlaxoSmithKline | Currently recruiting | Advanced |
47 | 40 | http://clinicaltrials.gov/ct2/show/NCT01461850 | Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasm (SCORPION) | Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasm | Patients with advanced ovarian cancer (FIGO stage III C) and highly disseminated tumor will be randomized into two arms: primary debulking surgery followed by adjuvant chemotherapy vs. neoadjuvant chemotherapy followed by interval debulking surgery (IDS). The primary end point is the evaluation and comparison of the surgical complications of primary surgery and IDS. | http://clinicaltrials.gov/ct2/show/NCT01461850 - Retrieved April 2012 | Catholic University of the Sacred Heart | Currently recruiting | Advanced | |
48 | 41 | http://clinicaltrials.gov/ct2/show/NCT01519869 | Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma | Neoadjuvant Platinum-based Chemotherapy in Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Trial Protocol | This is a prospective study to evaluate the hypothesis that platinum-based neoadjuvant chemotherapy followed by interval surgical debulking with platinum-based adjuvant chemotherapy is associated with improved maximal surgical cytoreduction rates, comparable survival, decreased morbidity, and increased quality of life in patients with International Federation of Gynecologic Oncology stages IIIC and IV ovarian, primary peritoneal, or fallopian tube cancer when compared to historical controls and to evaluate the hypothesis that cancer induced inflammation is a predictor of poor prognosis and response to therapy in this group of ovarian cancer patients. | http://clinicaltrials.gov/ct2/show/NCT01519869 - Retrieved April 2012 | University of Kentucky | Not yet recruiting | Advanced | |
49 | 42 | http://clinicaltrials.gov/ct2/show/NCT01550692 | Trial of Fenretinide/LXS Plus Ketoconazole in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma | Phase I/II Trial of Fenretinide/LXS Oral Powder (NSC 374551) Plus Ketoconazole in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma | The purpose of this study is to find out whether an investigational (non-FDA approved) drug called fenretinide (4-HPR) plus ketoconazole can treat recurrent ovarian better or more safely than standard medication. | http://clinicaltrials.gov/ct2/show/NCT01550692 - Retrieved April 2012 | University of Texas Southwestern Medical Center | South Plains Oncology Consortium | Not yet recruiting | Recurrent |
50 | 43 | http://clinicaltrials.gov/ct2/show/NCT00911079 | Ultrasound Hyperthermia Therapy After Implant Radiation Therapy in Treating Patients With Urinary Tract Cancer, Gynecologic Cancer, or Head and Neck Cancer | Pilot Study of a Catheter-based Ultrasound Hyperthermia System | This clinical trial is studying ultrasound hyperthermia therapy to see how well it works after implant radiation therapy in treating patients with urinary tract cancer, gynecologic cancer, or head and neck cancer. | http://clinicaltrials.gov/ct2/show/NCT00911079 - Retrieved April 2012 | University of California, San Francisco | National Cancer Institute | Currently recruiting | Recurrent / Metastatic |
51 | 44 | http://clinicaltrials.gov/ct2/show/NCT01459380 | Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | A Phase I Trial of Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin and NCI Supplied Veliparib (ABT-888) in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer | This randomized phase I trial studies the side effects and the best dose of veliparib given together with pegylated liposomal doxorubicin hydrochloride and carboplatin in treating patients with recurrent ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. | http://clinicaltrials.gov/ct2/show/NCT01459380 - Retrieved April 2012 | Gynecologic Oncology Group | National Cancer Institute | Currently recruiting | Recurrent |
52 | 45 | http://clinicaltrials.gov/ct2/show/NCT01196559 | Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer | A Phase II Study of Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Epithelial Ovarian/Fallopian Tube/ Primary Peritoneal Carcinoma. | The purpose of this study is to evaluate the objective response rate and safety in platinum-resistant epithelial ovarian/fallopian tube/primary peritoneal cancer patients treated with vinorelbine and gemcitabine combination chemotherapy. | http://clinicaltrials.gov/ct2/show/NCT01196559 - Retrieved April 2012 | The Catholic University of Korea | Korean Cancer Study Group | Currently recruiting | Recurrent |
53 | 46 | http://clinicaltrials.gov/ct2/show/NCT00602277 | Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy | A Phase 1 Study of Reovirus Serotype 3 - Dearing Strain (REOLYSIN®) (NSC 729968) in Patients With Ovarian, Primary Peritoneal and Fallopian Tube Carcinoma | This phase I/II trial is studying the side effects and best dose of viral therapy in treating patients with ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer that did not respond to platinum chemotherapy phase II closed as of 1/7/2011).. | http://clinicaltrials.gov/ct2/show/NCT00602277 - Retrieved April 2012 | Arthur G. James Cancer Hospital & Richard J. Solove Research Institute | National Cancer Institute | Currently recruiting | Recurrent |
54 | 47 | http://clinicaltrials.gov/ct2/show/NCT01294293 | VTX-2337 and Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | A Phase I Study of VTX-2337 (IND #78,416) in Combination With Doxil® (NSC# 712227) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | This phase I trial is studying the side effects and best dose of VTX-2337 and liposomal doxorubicin hydrochloride in treating patients with recurrent or persistent ovarian epithelial, fallopian tube, or peritoneal cavity cancer. | http://clinicaltrials.gov/ct2/show/NCT01294293 - Retrieved April 2012 | Gynecologic Oncology Group | National Cancer Institute | Currently recruiting | Recurrent |
55 | 48 | http://clinicaltrials.gov/ct2/show/NCT01144442 | WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer | WCC# 59: Pilot Study of Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence | This is an open-label, pilot study in patients with a diagnosis of recurrent ovarian, fallopian tube or primary peritoneal carcinoma who have undergone standard cytoreductive surgery following by adjuvant chemotherapy. It is expected that this first surgery was optimal - as defined as no residual tumor > or = 1 centimeter. Patient has clinical evidence of a first recurrence. The patient undergoes surgery and isotonic normal saline (perfusate) heated and administered into the abdomen, followed by hyperthermic intraperitoneal chemotherapy infusion (HIPC) administering carboplatin (chemotherapy). Six weeks after surgery patients will receive adjuvant chemotherapy with Paclitaxel and Carboplatin for 6 cycles. | http://clinicaltrials.gov/ct2/show/NCT01144442 - Retrieved April 2012 | Masonic Cancer Center, University of Minnesota | Currently recruiting | Recurrent | |
56 | 49 | http://clinicaltrials.gov/ct2/show/NCT01523678 | Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers | Phase II Study of Weekly Paclitaxel/Carboplatin in Combination With Prophylactic G-CSF in the Treatment of Gynaecological Cancers | Refer to clinical trials website. | http://clinicaltrials.gov/ct2/show/NCT01523678 - Retrieved April 2012 | Belgian Gynaecological Oncology Group | Currently recruiting | Recurrent | |
57 | ICAN advises every patient and other interested person, after reviewing this clinical trials spreadsheet, to check out clinical trials directly at www.cancer.gov in case there are updates since the date of this posting. ICAN does not purport to provide medical advice or to indicate which trial is suitable for a certain patient. Please consult your medical oncology team and the principal investigator in charge of the trial in which you are interested for information most relevant to your specific medical situation and decision-making process. | |||||||||
58 | ||||||||||
59 | ||||||||||
60 | ||||||||||
61 | ||||||||||
62 | ||||||||||
63 | ||||||||||
64 | ||||||||||
65 | ||||||||||
66 | ||||||||||
67 | ||||||||||
68 | ||||||||||
69 | ||||||||||
70 | ||||||||||
71 | ||||||||||
72 | ||||||||||
73 | ||||||||||
74 | ||||||||||
75 | ||||||||||
76 | ||||||||||
77 | ||||||||||
78 | ||||||||||
79 | ||||||||||
80 | ||||||||||
81 | ||||||||||
82 | ||||||||||
83 | ||||||||||
84 | ||||||||||
85 | ||||||||||
86 | ||||||||||
87 | ||||||||||
88 | ||||||||||
89 | ||||||||||
90 | ||||||||||
91 | ||||||||||
92 | ||||||||||
93 | ||||||||||
94 | ||||||||||
95 | ||||||||||
96 | ||||||||||
97 | ||||||||||
98 | ||||||||||
99 | ||||||||||
100 | ||||||||||